Table 4.

Univariate Five-State Markov Model for AMD Progression

SNP	Gene	Effective Allele/Genotype	Worse Eye Transition
			1 → 2		2 → 3		3 → 4		3 → 5
			HR*	P	HR*	P	HR*	P	HR*	P
rs1061170	CFH	C	1.01 (0.89, 1.16)	0.83	1.26 (1.09, 1.45)	1.3 × 10−3	1.62 (1.37, 1.91)	8.4 × 10−9	1.61 (1.37, 1.89)	5.3 × 10−9
rs10490924	ARMS2/HTRA1	T	1.14 (0.98, 1.33)	0.09	1.4 (1.2, 1.64)	2.8 × 10−5	1.51 (1.28, 1.78)	7.6 × 10−7	1.52 (1.29, 1.78)	3.4 × 10−7
rs9332739	C2	C†	0.9 (0.66, 1.23)	0.52	0.82 (0.55, 1.21)	0.31	0.56 (0.31, 1.03)	0.06	0.44 (0.23, 0.86)	0.02
rs641153	CFB	T†	0.91 (0.72, 1.16)	0.45	0.79 (0.59, 1.07)	0.13	0.64 (0.42, 0.97)	0.03	0.53 (0.34, 0.82)	4.3×10−3
rs2230199	C3	G	1.11 (0.95, 1.29)	0.18	1.2 (1.01, 1.42)	0.03	1.36 (1.13, 1.63)	9.4×10−4	1.3 (1.09, 1.55)	4.3×10−3
rs10033900	CFI	T	1.13 (1, 1.28)	0.05	1.03 (0.89, 1.18)	0.70	1.29 (1.09, 1.52)	3.2×10−3	0.95 (0.8, 1.11)	0.49
rs10468017	LIPC	TT†	0.71 (0.5, 1)	0.05	0.85 (0.56, 1.28)	0.44	0.81 (0.5, 1.31)	0.39	0.64 (0.38, 1.08)	0.10
rs9621532	TIMP3	C†	0.99 (0.73, 1.34)	0.94	1.06 (0.77, 1.47)	0.71	0.69 (0.44, 1.08)	0.11	0.71 (0.47, 1.09)	0.12
rs3764261	CETP	A	1.08 (0.94, 1.23)	0.28	1.03 (0.89, 1.2)	0.68	1 (0.84, 1.19)	0.99	1.27 (1.08, 1.49)	4.6×10−3
rs1883025	ABCA1	T	0.82 (0.71, 0.95)	7.8×10−3	0.79 (0.66, 0.95)	9.7×10−3	1 (0.82, 1.21)	0.97	1.02 (0.85, 1.23)	0.81
rs13095226	COL8A1	C†	1.13 (0.91, 1.4)	0.29	0.67 (0.49, 0.9)	8.0×10−3	1.55 (1.18, 2.04)	1.7×10−3	1.36 (1.04, 1.79)	0.03
APOE†	APOE	E4†	0.98 (0.8, 1.21)	0.87	0.91 (0.7, 1.17)	0.47	0.79 (0.58, 1.07)	0.12	0.88 (0.66, 1.17)	0.39

HR, hazard ratio for a specific transition.

^*P value is bold for variables significantly (P ≤ 0.05) associated with a specific transition.

^†Genotypes are combined at the marked SNPs, which are coded 0 for subjects without the effective allele/genotype and 1 for subjects with the effective allele/genotype. APOE haplotypes were defined by alleles in rs7412 and rs429358. SNPs not marked are coded by the number of effective alleles (0, 1, or 2).